Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04981925
Other study ID # HUM00187535
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date August 1, 2021
Est. completion date July 2025

Study information

Verified date October 2023
Source University of Michigan
Contact Elizabeth Banner
Phone 734-736-5226
Email eledward@med.umich.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The overall objective of this study is to better understand how Mindfulness-based Stress Reduction (MBSR) is the most helpful in terms of management of chronic pain symptoms. The studies hypothesis is that an Interventional Response Phenotyping study (light phenotyping) can identify individuals with different underlying mechanisms for their pain who thus respond differentially to evidence-based interventions for chronic pain disorders.


Description:

Participants enrolled in this study will receive 8 weeks of MBSR therapy and complete surveys at various time points pre-treatment - post treatment.


Recruitment information / eligibility

Status Recruiting
Enrollment 300
Est. completion date July 2025
Est. primary completion date July 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion criteria for MBSR Study - Ages 18+ - Any form of self-reported chronic pain (except cancer related pain) Exclusion criteria for MBSR study - Unable to speak and write English - Visual or hearing difficulties that would preclude participation - Chronic pain from cancer.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
MBSR treatment
Participants will complete pre-treatment surveys followed by 8-weekly 2-hour group sessions and one 4-hour "retreat" (may take place virtually or in-person). Participants will also be asked to practice daily formal mindfulness at home using assigned audio recordings of 30-45 minute guided mindfulness exercises. Participants will complete surveys during treatment as well as after treatment and then at 2 months follow-up.

Locations

Country Name City State
United States University of Michigan Ann Arbor Michigan

Sponsors (1)

Lead Sponsor Collaborator
University of Michigan

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary PROMIS physical function 6b Physical Function 6b questionnaire will assess self-reported capability with 6 qualitatively scaled questions ranked on a 5-point scale, from "without any difficulty" to "unable to do" or "not at all" to "cannot do." The minimum raw summed score is 6 and the maximum score is 30. Lower scores suggest better outcomes. 8 weeks (after MSBR)
Secondary Change in PROMIS pain intensity, anxiety, pain interference Change from baseline in pain interference (QoL), measured by PROMIS Pain Interference 6a. Measure of the amount of interference pain causes in life; range 6-30; higher is worse Baseline (pre-treatment), 8 weeks
Secondary Change in PROMIS pain intensity, anxiety, pain interference Change from baseline in pain interference (QoL), measured by PROMIS Pain Interference 6a. Measure of the amount of interference pain causes in life; range 6-30; higher is worse Baseline (pre-treatment), 8 and 12 weeks
Secondary Change in Pain Catastrophizing Scale (PCS) The PCS is a 13-item questionnaire that inquires about thoughts and feelings a patient experiences when in pain. Responses are recorded on a 5-point Likert scale ("not at all" to "all the time"). A total score is yielded ranging from 0-52. Higher score is associated with worse outcome. Baseline (pre-treatment), 8 and 12 weeks
Secondary Pain Catastrophizing Score; measured with Pain Catastrophizing Scale The PCS is a 13-item questionnaire that inquires about thoughts and feelings a patient experiences when in pain. Responses are recorded on a 5-point Likert scale ("not at all" to "all the time"). A total score is yielded ranging from 0-52. Higher score is associated with worse outcome 8 weeks (after MSBR)
Secondary Change in Chronic Pain Acceptance Questionnaire (CPAQ)-8 CPAQ-8 is an 8-item questionnaire with a score range 0-48 with higher scores indicating better status. Change score is computed by subtracting baseline CPAQ-8 score from score at time of reassessment. Improvement is indicated by change scores with positive values. Baseline, 8 weeks (after MSBR)
See also
  Status Clinical Trial Phase
Recruiting NCT01417923 - The Immune and Clinical Impacts of Vitamin D in Patients With Chronic Musculo-skeletal Pain Phase 4
Completed NCT03472521 - Prevention of Persistent Opioid Use in Mothers Phase 4
Not yet recruiting NCT03249025 - Lidocaine-Ketamine for Management of Chronic Pain N/A
Enrolling by invitation NCT06359561 - Assessment of Effectiveness and Stimulation Coverage of Closed-loop Spinal Cord Stimulation (CL-SCS) Therapy in Patients With Cervical Lead Placement
Recruiting NCT05877274 - Sodium Channel Mutations in Patient With the Anterior Cutaneous Nerve Entrapment Syndrome (ACNES)
Completed NCT03317782 - NoL Index Variations Before and After a Stellate Ganglion Block
Completed NCT04199858 - Electrophysiological Correlates of Nocebo Effects on Pain N/A
Recruiting NCT05491499 - Assessing the Impact of Exercise Based Intensive Interdisciplinary Pain Treatment (IIPT) on Endogenous Pain Modulation in Youth With Chronic Pain Syndromes
Active, not recruiting NCT05090683 - Evaluation of a Mind-body Based Application for the Treatment of Chronic/Persistent Pain. N/A
Completed NCT04197154 - Pain-related Fear as a Facilitator of Nocebo Hyperalgesia N/A
Completed NCT04209764 - Prevalence of Pain in the Departments of Surgery and Oncoematology of a Children's Hospital
Recruiting NCT06071975 - Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Diabetic Polyneuropathy Phase 3
Recruiting NCT06072573 - Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Diabetic Polyneuropathy Phase 3
Recruiting NCT06072001 - Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis Phase 3
Recruiting NCT06072560 - Efficacy and Tolerability of AP707 in Patients With Chronic Back Pain Phase 3
Recruiting NCT06071936 - Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Traumatic or Post-operative Peripheral Neuropathy Phase 3
Recruiting NCT06071962 - Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Back Pain Phase 3
Recruiting NCT06071949 - Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis Phase 3
Recruiting NCT06071988 - Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Traumatic or Post-operative Peripheral Neuropathy Phase 3
Completed NCT03460717 - Thermal Micro-cautery for Painful Knee Osteoarthritis N/A